Summary.-The transplantable Guerin epithelioma in Wistar rats was used to test the in vivo effectiveness of 1-(2-hydroxy-3-methoxypropyl)-2-methyl-4-nitroimidazole (P1) as a tumour-cell radiosensitizer after its oral administration at relatively low doses. The radiosensitizing ability of P1 was compared with that of metronidazole. The results indicate that P1 is less toxic than metronidazole, and greater concentrations of P1 in blood and tumour tissues are obtained for the same administered dose of the compounds. The radiosensitizing ability of P1, determined from tumour-regression rates and local-control percentage at 130 days, was higher than that of metronidazole.
UP TO NOW, the 4-iiitroimidlazoles as radiosensitizers of hypoxic tumour cells have been less well investigated than 2-and 5-nitroimidazole compounds (Rauth et al., 1978) . Therefore, a closer investigation of this problem seems to be necessary and the results may be of importance in clinical radiotherapy. This paper describes preliminary results of experiments with Compound P1 as a radiosensitizer performed on a tumour system in vivo.
MATERIALS AND AIETHODS
Anti//al and tumour system. Inbred male Wistar rats were used at an age of about 3 months. The solid Guerin epithelioma (Guerin & Guerin, 1934) has been passaged for many generations in this laboratory. This tumour has a volume-doubling time during the exponential period of growAth in the range of 3-14-3 days, with a mean of 3-7 + 0-6 days. From 2 weeks after transplantation, macroscopically visible metastases appeared frequently, especially in the lymph nodes. The mean survival time of the untreated tumourbearing animals was 32 + 3 days after transplantation. The tumours were implanted s.c. as fragments ( 2() m13 in SiZe) in the right dorsal region of rats. Freely movable tumours at a size of 0 83-0 95 cm3. without perceptible metastases and -without skin and muscle infiltration, were used for experiments, on the average 2 wreeks after transplantation.
The compounds studied. Metronidazole was obtained from "Polfa". The cornpound Pi was synthesized by us (Suwvifiski et al., 1978) . Structures of the compounds and some of their properties are shown in Table 1 . Both nitroimidazoles wvere given orally dissolved in water (P1) or in suspension (mnetronidazole) at doses of 0 15-0 6 g/kg body wt. P1 was administered 60 min and metronidazole 90 min before each irradiation. The concentration of compounds in blood and tumour tissue wvas estimated in the ethanol supernatants by spectrophotometry at 314 nm (metronidazole) and 302 nm (P1), according to the method described by Urtasun et al. (1975) .
Pi acute toxicity test.-The LD50 was determined by giving animals (C3H mice and Wistar rats) graded doses of compound P1 orally and observing deaths among the animals at 2 and 30 days.
Evaluation of cytotoxicity on tumour.-Experimental groups of 10 tumour-bearing rats with a mean tumour volume of 0 9 cm3 were Lower toxicity of P1 in comparison with metronidazole was also indicated by a smaller decrease of body wt of rats after 10 doses of P1 given orally every second day at a dose of 0 3 g/kg body wt. The rats' body-wt losses were 12-0 + 6 g for the P1 group and 46-0 + 9 g for the metronidazole group when the average untreated rats weighed 348 + 7 g.
The above data, assayed in vivo, are in P1 is characterized by a rapid accumulation and it quickly reaches peak concentrations. After all 3 doses, the peak concentration of Pi in blood was reached at 45-60 min and was 0 7, 1P0 and 1-9 mM respectively. In the tumour tissue at the same doses the peak concentration appeared at similar or slightly later times, and reached 75-88% of peak blood concentrations.
Wtith regard to metronidazole, after doses of 0 3 and 0 6 g/kg body wt peak concentration in the blood, 0 7 and 1-2 mm, was reached at 60-120 min and at 90-120 min in the tumour (0.6 and 1-0 mmol/kg). At both doses the tumour levels reached 83-86% of peak blood values. Thus, after administration of equal doses (0 3 and 0-6 g/kg body wt) the concentration of P1 in the blood and tumour tissue is -15 times more than that of metronidazole; after doses of 0 15 g/kg P1 and 0 3 g/kg metronidazole the concentrations are quite similar. The shape of the regression curves (Fig. 3) is similar for all 3 doses of P1. The proportions of rats without palpable tumour at 45 days (Table II) but effective quantities of radiosensitizers, nitroimidazoles (P1 or metronidazole) in further experiments were administered in doses of 0 3 g/kg body wt. The effects of fractionated irradiation combined with radiosensitizers at these doses on tumour regression rates and local control percentage in a representative experiment are shown in Fig. 4(A, B) plete killing of all tumour cells (Fig. 4(A) ). mV') and Pi (El7= -564 mA) at concentrations within the range 01-1P0 mm (or mmol/kg), the SER-determining factor would be rather the compound tissue concentration than its E17. The better results in the in vivo experiments with PI seeml to confirm this assumption. Irradiation combined with P1 or metroniidazole also prevents the formation of metastases (Table III) . A distinct correlation exists between total and possibly early eradication of primary tumour and an absence of metastases. However, taking into account the small numbers of animals in the experimental groups, the data are not statistically significant.
Regression of the tumour volume in individual experimental groups, as shown in Fig. 4 , indicates a correlation between shrinkage during therapy and the probability of local control at 130 days (Table  III) . This correlation is widely discussed by Denekamp (1 977) and our results are in good agreement, with her suggestions. 
